Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2026-05-14 Proxy Solicitation & In…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Ogłoszenie o zwołaniu NWZ na dzień 10.06.2026
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice (“Ogłoszenie Zarządu”) convening an Extraordinary General Meeting of Pure Biologics S.A., detailing the date, agenda items (capital increases, statutory changes), registration date, participant rights, and proxy procedures. It is not the report itself but materials provided to shareholders to solicit attendance and votes. This matches the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-14 Polish
Informacja o zwołaniu Nadzwyczajnego Walnego Zgromadzenia Pure Biologics S.A. wraz z treścią projektów uchwał - Content (PL)
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a convocation notice for an Extraordinary General Meeting, including the draft resolutions, management report, and auditor’s opinion, i.e. materials provided to shareholders to inform and solicit votes. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-14 Polish
Lista akcjonariuszy posiadających co najmniej 5% głosów na Nadzwyczajnym Walnym Zgromadzeniu Pure Biologics S.A. 14 maja 2026 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is an official public disclosure listing shareholders holding at least 5% of voting rights at an Extraordinary General Meeting (NWZ) held on 14 May 2026. It does not present full financial statements or describe management changes, nor is it a notification of a specific individual shareholding change. Instead, it provides voting rights details and attendance figures for the general meeting. This matches the Declaration of Voting Results & Voting Rights Announcements category (Code: DVA).
2026-05-14 Polish
Treść uchwał NWZ Pure Biologics S.A. z dnia 14.05.2026
Share Issue/Capital Change Classification · 85% confidence The document comprises formal resolutions of an Extraordinary General Meeting of Pure Biologics S.A., including voting outcomes and detailed share issuance/capital increase decisions (new series Q, R, S shares, pre-emptive rights exclusions, statutory amendments, dematerialisation and listing steps). This aligns with a Share Issue/Capital Change announcement.
2026-05-14 Polish
Treść uchwał podjętych oraz uchwał niepoddanych pod głosowanie przez Nadzwyczajne Walne Zgromadzenie Pure Biologics S.A. 14 maja 2026 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document provides the resolutions adopted and not put to vote by the Extraordinary General Meeting held on May 14, 2026, along with the number of shares voted, percentage of share capital, and votes “for”, “against” and “abstained”. This is a formal declaration of voting results from a general meeting, matching the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-14 Polish
Zmiana terminu publikacji raportu kwartalnego za I kwartał 2026 r. - Content (PL)
Report Publication Announcement Classification · 80% confidence The document is a brief notice informing investors of a change in the publication date for the Q1 2026 report. It contains no financial statements or substantive data, only an announcement of timing of a forthcoming report. Under the “menu vs meal” rule, this is a report publication announcement rather than the interim report itself.
2026-05-12 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.